{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:03:23Z","timestamp":1792029803948,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Science and Technology Planning Project of Guangzhou"},{"name":"Guangdong Medical Science and Technology Research Foundation"},{"name":"Guangzhou Municipal Science and Technology Plan Project"},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Project supported by the KPT Plan of Guangdong Medical Development Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-025-04512-3","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T01:47:09Z","timestamp":1745200029000},"page":"3365-3371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Effectiveness and safety of finerenone in the treatment of IgA Nephrology patients: a retrospective, real-world study"],"prefix":"10.1007","volume":"57","author":[{"given":"Qingqing","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haowen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zewen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhe","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianchao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonglin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"key":"4512_CR1","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1056\/NEJMra1206793","volume":"368","author":"RJ Wyatt","year":"2013","unstructured":"Wyatt RJ, Julian BA (2013) IgA nephropathy. N Engl J Med 368:2402\u20132414. https:\/\/doi.org\/10.1056\/NEJMra1206793","journal-title":"N Engl J Med"},{"key":"4512_CR2","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1053\/j.ajkd.2021.01.024","volume":"78","author":"P Pattrapornpisut","year":"2021","unstructured":"Pattrapornpisut P, Avila-Casado C, Reich HN (2021) IgA nephropathy: core curriculum 2021. Am J Kidney Dis 78:429\u2013441. https:\/\/doi.org\/10.1053\/j.ajkd.2021.01.024","journal-title":"Am J Kidney Dis"},{"key":"4512_CR3","doi-asserted-by":"publisher","unstructured":"Chen D, Zhang Z, Yang Y, et al (2019) High-throughput sequencing analysis of genes encoding the B-lymphocyte receptor heavy-chain CDR3 in renal and peripheral blood of IgA nephropathy. Biosci Rep 39:BSR20190482. https:\/\/doi.org\/10.1042\/BSR20190482","DOI":"10.1042\/BSR20190482"},{"key":"4512_CR4","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1093\/ckj\/sfab244","volume":"15","author":"A Huerta","year":"2022","unstructured":"Huerta A, M\u00e9rida E, Medina L et al (2022) Corticosteroids and mycophenolic acid analogues in immunoglobulin A nephropathy with progressive decline in kidney function. Clin Kidney J 15:771\u2013777. https:\/\/doi.org\/10.1093\/ckj\/sfab244","journal-title":"Clin Kidney J"},{"key":"4512_CR5","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00281-021-00888-3","volume":"43","author":"J Floege","year":"2021","unstructured":"Floege J, Rauen T, Tang SCW (2021) Current treatment of IgA nephropathy. Semin Immunopathol 43:717\u2013728. https:\/\/doi.org\/10.1007\/s00281-021-00888-3","journal-title":"Semin Immunopathol"},{"key":"4512_CR6","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.autrev.2014.01.030","volume":"13","author":"H-H Yu","year":"2014","unstructured":"Yu H-H, Chiang B-L (2014) Diagnosis and classification of IgA nephropathy. Autoimmun Rev 13:556\u2013559. https:\/\/doi.org\/10.1016\/j.autrev.2014.01.030","journal-title":"Autoimmun Rev"},{"key":"4512_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.813603","volume":"9","author":"G Yu","year":"2022","unstructured":"Yu G, Cheng J, Jiang Y et al (2022) Intensive systolic blood pressure lowering and kidney disease progression in IGA nephropathy: a cohort study. Front Med 9:813603. https:\/\/doi.org\/10.3389\/fmed.2022.813603","journal-title":"Front Med"},{"key":"4512_CR8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1053\/j.ajkd.2019.11.008","volume":"76","author":"G Yu","year":"2020","unstructured":"Yu G, Guo L, Dong J et al (2020) Persistent hematuria and kidney disease progression in IgA nephropathy: a cohort study. Am J Kidney Dis 76:90\u201399. https:\/\/doi.org\/10.1053\/j.ajkd.2019.11.008","journal-title":"Am J Kidney Dis"},{"key":"4512_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/ki.2015.322","volume":"89","author":"SJ Barbour","year":"2016","unstructured":"Barbour SJ, Espino-Hernandez G, Reich HN et al (2016) The MEST score provides earlier risk prediction in lgA nephropathy. Kidney Int 89:167\u2013175. https:\/\/doi.org\/10.1038\/ki.2015.322","journal-title":"Kidney Int"},{"key":"4512_CR10","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1001\/jamainternmed.2019.0600","volume":"179","author":"SJ Barbour","year":"2019","unstructured":"Barbour SJ, Coppo R, Zhang H et al (2019) Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med 179:942. https:\/\/doi.org\/10.1001\/jamainternmed.2019.0600","journal-title":"JAMA Intern Med"},{"key":"4512_CR11","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1097\/MNH.0000000000000405","volume":"27","author":"S Barbour","year":"2018","unstructured":"Barbour S, Reich H (2018) An update on predicting renal progression in IgA nephropathy. Curr Opin Nephrol Hypertens 27:214\u2013220. https:\/\/doi.org\/10.1097\/MNH.0000000000000405","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"4512_CR12","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2215\/CJN.08600718","volume":"14","author":"A Thompson","year":"2019","unstructured":"Thompson A, Carroll K, Inker LA et al (2019) Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol 14:469\u2013481. https:\/\/doi.org\/10.2215\/CJN.08600718","journal-title":"Clin J Am Soc Nephrol"},{"key":"4512_CR13","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/j.ajkd.2016.02.042","volume":"68","author":"LA Inker","year":"2016","unstructured":"Inker LA, Mondal H, Greene T et al (2016) Early change in urine protein as a surrogate end point in studies of IgA nephropathy: an individual-patient meta-analysis. Am J Kidney Dis 68:392\u2013401. https:\/\/doi.org\/10.1053\/j.ajkd.2016.02.042","journal-title":"Am J Kidney Dis"},{"key":"4512_CR14","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1681\/ASN.2007050526","volume":"18","author":"HN Reich","year":"2007","unstructured":"Reich HN, Troyanov SAA, Scholey JW, Cattran DC (2007) Remission of proteinuria improves prognosis in IgA Nephropathy. J Am Soc Nephrol 18:3177\u20133183. https:\/\/doi.org\/10.1681\/ASN.2007050526","journal-title":"J Am Soc Nephrol"},{"key":"4512_CR15","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1053\/j.ajkd.2012.02.326","volume":"59","author":"SJ Barbour","year":"2012","unstructured":"Barbour SJ, Reich HN (2012) Risk stratification of patients with IgA Nephropathy. Am J Kidney Dis 59:865\u2013873. https:\/\/doi.org\/10.1053\/j.ajkd.2012.02.326","journal-title":"Am J Kidney Dis"},{"key":"4512_CR16","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/ki.2014.63","volume":"86","author":"R Coppo","year":"2014","unstructured":"Coppo R, Troyanov S, Bellur S et al (2014) Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int 86:828\u2013836. https:\/\/doi.org\/10.1038\/ki.2014.63","journal-title":"Kidney Int"},{"key":"4512_CR17","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1093\/ndt\/gfr527","volume":"27","author":"W Le","year":"2012","unstructured":"Le W, Liang S, Hu Y et al (2012) Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant 27:1479\u20131485. https:\/\/doi.org\/10.1093\/ndt\/gfr527","journal-title":"Nephrol Dial Transplant"},{"key":"4512_CR18","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD et al (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383:2219\u20132229. https:\/\/doi.org\/10.1056\/NEJMoa2025845","journal-title":"N Engl J Med"},{"key":"4512_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-024-04142-1","author":"L Zhou","year":"2024","unstructured":"Zhou L, Li W (2024) Effectiveness and safety of finerenone in Chinese CKD patients without diabetes: a retrospective, real-world study. Int Urol Nephrol. https:\/\/doi.org\/10.1007\/s11255-024-04142-1","journal-title":"Int Urol Nephrol"},{"key":"4512_CR20","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.kint.2019.07.009","volume":"96","author":"J Floege","year":"2019","unstructured":"Floege J (2019) A new tool to predict the risk of progression in IgA nephropathy. Kidney Int 96:808\u2013809. https:\/\/doi.org\/10.1016\/j.kint.2019.07.009","journal-title":"Kidney Int"},{"key":"4512_CR21","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J et al (2021) KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100:S1\u2013S276. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021","journal-title":"Kidney Int"},{"key":"4512_CR22","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1053\/j.ajkd.2023.12.016","volume":"84","author":"C Tang","year":"2024","unstructured":"Tang C, Chen P, Si F-L et al (2024) Time-varying proteinuria and progression of IgA nephropathy: a cohort study. Am J Kidney Dis 84:170-178.e1. https:\/\/doi.org\/10.1053\/j.ajkd.2023.12.016","journal-title":"Am J Kidney Dis"},{"key":"4512_CR23","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/ddr.21760","volume":"82","author":"V Patel","year":"2021","unstructured":"Patel V, Joharapurkar A, Jain M (2021) Role of mineralocorticoid receptor antagonists in kidney diseases. Drug Dev Res 82:341\u2013363. https:\/\/doi.org\/10.1002\/ddr.21760","journal-title":"Drug Dev Res"},{"key":"4512_CR24","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1161\/hypertensionaha.121.17263","volume":"78","author":"D Hirohama","year":"2021","unstructured":"Hirohama D, Nishimoto M, Ayuzawa N et al (2021) Activation of Rac1-mineralocorticoid receptor pathway contributes to renal injury in salt-loaded db\/db mice. Hypertension 78:82\u201393. https:\/\/doi.org\/10.1161\/hypertensionaha.121.17263","journal-title":"Hypertension"},{"key":"4512_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.110210","volume":"195","author":"Q Chen","year":"2023","unstructured":"Chen Q, Liang Y, Yan J et al (2023) Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists for renal outcomes: a systematic review and meta-analysis. Diabetes Res Clin Pract 195:110210. https:\/\/doi.org\/10.1016\/j.diabres.2022.110210","journal-title":"Diabetes Res Clin Pract"},{"key":"4512_CR26","doi-asserted-by":"publisher","first-page":"1213473","DOI":"10.3389\/fimmu.2023.1213473","volume":"14","author":"Z-C Dai","year":"2023","unstructured":"Dai Z-C, Chen J-X, Zou R et al (2023) Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease. Front Immunol 14:1213473. https:\/\/doi.org\/10.3389\/fimmu.2023.1213473","journal-title":"Front Immunol"},{"key":"4512_CR27","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.jfma.2020.07.022","volume":"120","author":"Y-T Chen","year":"2021","unstructured":"Chen Y-T, Chan C-K, Li W-Y et al (2021) Renin-angiotensin-aldosterone system inhibition decreased contrast-associated acute kidney injury in chronic kidney disease patients. J Formos Med Assoc 120:641\u2013650. https:\/\/doi.org\/10.1016\/j.jfma.2020.07.022","journal-title":"J Formos Med Assoc"},{"key":"4512_CR28","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1093\/ajhp\/57.suppl_1.S3","volume":"57","author":"RW Piepho","year":"2000","unstructured":"Piepho RW (2000) Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm 57:S3\u2013S7. https:\/\/doi.org\/10.1093\/ajhp\/57.suppl_1.S3","journal-title":"Am J Health Syst Pharm"},{"key":"4512_CR29","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383:1436\u20131446. https:\/\/doi.org\/10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"4512_CR30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","volume":"9","author":"DC Wheeler","year":"2021","unstructured":"Wheeler DC, Stef\u00e1nsson BV, Jongs N et al (2021) Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 9:22\u201331. https:\/\/doi.org\/10.1016\/S2213-8587(20)30369-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4512_CR31","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41574-019-0275-6","volume":"15","author":"J Wilding","year":"2019","unstructured":"Wilding J (2019) SGLT2 inhibitors and urinary tract infections. Nat Rev Endocrinol 15:687\u2013688. https:\/\/doi.org\/10.1038\/s41574-019-0275-6","journal-title":"Nat Rev Endocrinol"},{"key":"4512_CR32","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40262-021-01082-2","volume":"61","author":"P Van Den Berg","year":"2022","unstructured":"Van Den Berg P, Ruppert M, Mesic E et al (2022) Finerenone dose-exposure-response for the primary kidney outcome in FIDELIO-DKD phase III: population pharmacokinetic and time-to-event analysis. Clin Pharmacokinet 61:439\u2013450. https:\/\/doi.org\/10.1007\/s40262-021-01082-2","journal-title":"Clin Pharmacokinet"},{"key":"4512_CR33","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1080\/13543784.2021.2002844","volume":"30","author":"J Barrera-Chimal","year":"2021","unstructured":"Barrera-Chimal J, Kolkhof P, Lima-Posada I et al (2021) Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics. Expert Opin Investig Drugs 30:1141\u20131157. https:\/\/doi.org\/10.1080\/13543784.2021.2002844","journal-title":"Expert Opin Investig Drugs"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04512-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04512-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04512-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T14:00:12Z","timestamp":1758808812000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04512-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["4512"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04512-3","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]},"assertion":[{"value":"16 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no commercial or financial relationships that could be construed as potential conflicts of interest in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study has obtained written informed consent from all participants to include their clinical and imaging data in this manuscript for the purpose of publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"This study followed the ethical guidelines of Guangdong Provincial People's Hospital, with the ethical approval number KY2024-722-01.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}